Boston Trust Walden Corp Purchases 439,281 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Boston Trust Walden Corp grew its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 81.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 978,920 shares of the company's stock after buying an additional 439,281 shares during the period. Boston Trust Walden Corp owned approximately 2.04% of Amphastar Pharmaceuticals worth $36,347,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in AMPH. GAMMA Investing LLC grew its position in Amphastar Pharmaceuticals by 70.0% in the third quarter. GAMMA Investing LLC now owns 663 shares of the company's stock worth $32,000 after acquiring an additional 273 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. lifted its stake in shares of Amphastar Pharmaceuticals by 53.4% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company's stock valued at $56,000 after purchasing an additional 398 shares during the last quarter. Asset Management One Co. Ltd. purchased a new position in shares of Amphastar Pharmaceuticals in the 3rd quarter worth approximately $78,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Amphastar Pharmaceuticals by 20.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company's stock valued at $85,000 after purchasing an additional 301 shares during the last quarter. Finally, KBC Group NV raised its holdings in Amphastar Pharmaceuticals by 43.1% during the 4th quarter. KBC Group NV now owns 2,159 shares of the company's stock valued at $80,000 after buying an additional 650 shares during the period. 65.09% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have commented on AMPH shares. StockNews.com lowered shares of Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, November 1st. Wells Fargo & Company started coverage on shares of Amphastar Pharmaceuticals in a report on Friday, November 22nd. They set an "equal weight" rating and a $55.00 price target on the stock. Finally, Piper Sandler downgraded shares of Amphastar Pharmaceuticals from an "overweight" rating to a "neutral" rating and decreased their price objective for the stock from $66.00 to $36.00 in a research note on Tuesday. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat.com, Amphastar Pharmaceuticals currently has a consensus rating of "Hold" and a consensus price target of $50.33.

Insider Activity

In related news, EVP Rong Zhou sold 6,893 shares of Amphastar Pharmaceuticals stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $48.88, for a total value of $336,929.84. Following the completion of the sale, the executive vice president now directly owns 118,388 shares in the company, valued at $5,786,805.44. The trade was a 5.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Richard K. Prins sold 5,000 shares of the stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $48.80, for a total transaction of $244,000.00. Following the transaction, the director now owns 31,471 shares in the company, valued at approximately $1,535,784.80. The trade was a 13.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 28,893 shares of company stock valued at $1,329,570. Corporate insiders own 27.10% of the company's stock.

Amphastar Pharmaceuticals Trading Down 1.3 %

Shares of AMPH traded down $0.42 during trading hours on Friday, reaching $32.37. 311,540 shares of the company traded hands, compared to its average volume of 541,086. The firm has a market cap of $1.56 billion, a price-to-earnings ratio of 10.79, a PEG ratio of 1.07 and a beta of 0.81. Amphastar Pharmaceuticals, Inc. has a 12-month low of $32.16 and a 12-month high of $56.45. The stock's fifty day moving average price is $38.39 and its 200 day moving average price is $43.73. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.